Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 1/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | GSK3B | P49841 | 2/20 | 0.68 |
| ▸ | PIM1 | P11309 | 11/20 | 0.58 |
| ▸ | PIM2 | Q9P1W9 | 11/20 | 0.58 |
| ▸ | IGF1R | P08069 | 1/20 | 0.56 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.55 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | MAOA | P21397 | 2/20 | 0.54 |
| ▸ | MAOB | P27338 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | CISD1 | Q9NZ45 | 3/20 | 0.54 |
| ▸ | TTR | P02766 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29676493 | 1.00 | RAB9A (1.00) | RAB9APIK3CAPIK3CGNPC1GSK3B | |
| SCHEMBL1804516 | 1.00 | RAB9A (1.00) | RAB9APIK3CAPIK3CGNPC1GSK3B | |
| SCHEMBL29366360 | 1.00 | RAB9A (1.00) | RAB9APIK3CAPIK3CGNPC1GSK3B | |
| SCHEMBL1804517 | 1.00 | RAB9A (1.00) | RAB9APIK3CAPIK3CGNPC1GSK3B | |
| SCHEMBL1804519 | 0.82 | PIK3CA (0.70) | RAB9APIK3CAPIK3CGNPC1GSK3B | |
| SCHEMBL497276 | 0.81 | NPC1 (0.67) | RAB9APIK3CAPIK3CGNPC1GSK3B | |
| SCHEMBL497277 | 0.81 | NPC1 (0.67) | RAB9APIK3CAPIK3CGNPC1GSK3B | |
| SCHEMBL1249098 | 0.81 | GSK3B (0.83) | RAB9APIK3CAPIK3CGNPC1GSK3B | |
| SCHEMBL2882197 | 0.81 | GSK3B (0.83) | RAB9APIK3CAPIK3CGNPC1GSK3B | |
| SCHEMBL6796814 | 0.81 | GSK3B (1.00) | RAB9APIK3CAPIK3CGNPC1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846925-B2 | Azolidinone-vinyl fused-benzene derivatives | MERCK SERONO SA (CH) | 2010-12-07 | — | — | US | claimed |
| US-20090042773-A1 | P13 kinase gamma inhibitors for the treatment of anaemia | MERCK SERONO SA (CH) | 2009-02-12 | — | — | US | claimed |
| EP-1807075-A2 | PI3 KINASE GAMMA INHIBITORS FOR THE TREATMENT OF ANAEMIA | Applied Research Systems ARS Holding N.V. (AN) | 2007-07-18 | — | — | EP | claimed |
| US-20060122176-A1 | Azolidinone-vinyl fused-benzene derivatives | MERCK SERONO SA (CH) | 2006-06-08 | — | — | US | claimed |
| WO-2006040318-A2 | PI3 KINASE GAMMA INHIBITORS FOR THE TREATMENT OF ANAEMIA | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-04-20 | — | — | WO | claimed |
| US-20050222225-A1 | Use of compounds for increasing spermatozoa motility | APPLIED RESEARCH SYSTEMS ARS HOLDING NV (NL) | 2005-10-06 | — | — | US | claimed |
| EP-1549644-A1 | AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES | Applied Research Systems ARS Holding N.V. (AN) | 2005-07-06 | — | — | EP | claimed |
| EP-1531813-A1 | USE OF COMPOUNDS FOR INCREASING SPERMATOZOA MOTILITY | Applied Research Systems ARS Holding N.V. (AN) | 2005-05-25 | — | — | EP | claimed |
| WO-2004007491-A1 | AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2004-01-22 | — | — | WO | claimed |
| WO-2004006916-A1 | USE OF COMPOUNDS FOR INCREASING SPERMATOZOA MOTILITY | APPLIED RESEARCH SYSTEMS ARS HOLDING NV (AN) | 2004-01-22 | — | — | WO | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20230201202-A1 | COMPOSITIONS AND METHODS FOR SENSITIZING ACUTE MYELOID LEUKEMIAS TO CHEMOTHERAPY | DUKE UNIVERSITY | 2023-06-29 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20050222225-A1 | Use of compounds for increasing spermatozoa motility | APPLIED RESEARCH SYSTEMS ARS HOLDING NV (NL) | 2005-10-06 | — | — | US | disclosed |
| EP-1549644-A1 | AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES | Applied Research Systems ARS Holding N.V. (AN) | 2005-07-06 | — | — | EP | disclosed |
| EP-1531813-A1 | USE OF COMPOUNDS FOR INCREASING SPERMATOZOA MOTILITY | Applied Research Systems ARS Holding N.V. (AN) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004007491-A1 | AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004006916-A1 | USE OF COMPOUNDS FOR INCREASING SPERMATOZOA MOTILITY | APPLIED RESEARCH SYSTEMS ARS HOLDING NV (AN) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042773-A1 | P13 kinase gamma inhibitors for the treatment of anaemia | PDPK1, PRKD3, PRKD1 | RAB9A 1524/4885PIK3CA 17/4885PIK3CG 52/4885 |
| US-20050222225-A1 | Use of compounds for increasing spermatozoa motility | CATSPER1, PI4KB, MAN2B2 | RAB9A 1737/4885PIK3CA 130/4885PIK3CG 110/4885 |
| US-20060122176-A1 | Azolidinone-vinyl fused-benzene derivatives | BRCA1, ZAP70, F13B | RAB9A 1504/4885PIK3CA 559/4885PIK3CG 1318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.